Video

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Chemotherapy is a preferred treatment option for patients with high-risk disease, Adelstein explains. Evidence suggests that the use of high-dose cisplatin benefits select patients in terms of locoregional control and survival. However, there is less evidence showing that weekly treatment with cisplatin is as effective.

No data suggest that carboplatin, cetuximab, or taxane-based therapies in the adjuvant setting have a role in these patients. Radiation therapy has also shown to be a reasonable approach in patients who are unable to tolerate cisplatin.

<<<

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Yungan Tao, MD
Jared Weiss, MD
Lillian L. Siu, MD, FRCPC